<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1359">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513990</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0318</org_study_id>
    <secondary_id>NCI-2020-03470</secondary_id>
    <secondary_id>2020-0318</secondary_id>
    <nct_id>NCT04513990</nct_id>
  </id_info>
  <brief_title>Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)</brief_title>
  <acronym>END CoV-2</acronym>
  <official_title>Evaluation of a Novel Point-of-Care Diagnostic Test for SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>William Marsh Rice University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates a new diagnostic test in detecting SARS-CoV-2, the virus that causes
      the disease COVID-19. This may help to improve testing for COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To evaluate the clinical performance of a novel point-of-care diagnostic test for
      detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes
      the disease called coronavirus disease 19 (COVID-19).

      SECONDARY OBJECTIVES:

      I. To compare the clinical performance of provider-collected nasopharyngeal samples with
      self-collected nasal swab, cheek swab, and saliva sample using the novel SARS-CoV-2
      diagnostic test.

      II. To measure viral load and evaluate the role of viral load in COVID-19 severity.

      OUTLINE:

      Participants undergo collection of nasopharyngeal (back of the nose) samples by a medical
      provider and self-collection of oral, saliva, and nasal samples.

      After completion of study, participants are followed up at 1 month.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of diagnostic test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will use the standard-of-care (real time polymerase chain reaction [RT-PCR]) coronavirus disease 19 (COVID-19) test at the MD Anderson Molecular Diagnostic Lab result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the true result to estimate sensitivity with 95% confidence intervals. Estimates of sensitivity and specificity of the novel point-of-care diagnostic test will be provided separately for the provider-collected nasopharyngeal samples, the self-collected nasal swab, and the self-collected cheek swab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of diagnostic test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will use the standard-of-care (RT-PCR) COVID-19 test at the MD Anderson Molecular Diagnostic Lab result for SARS-CoV-2 as the true result to estimate specificity with 95% confidence intervals. Estimates of sensitivity and specificity of the novel point-of-care diagnostic test will be provided separately for the provider-collected nasopharyngeal samples, the self-collected nasal swab, and the self-collected cheek swab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance of the novel point-of-care diagnostic test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated with 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive predictive value (PPV) of the novel point-of-care diagnostic test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated with 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative predictive value (NPV) of the novel point-of-care diagnostic test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated with 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load metrics</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Will use descriptive statistics to summarize viral load metrics from the standard-of-care (RT-PCR) SARS-CoV-2 test and from each of the point-of-care tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Will use logistic regression methods to model progression to severe disease (defined as hospitalization) as a function of viral load, age, gender, smoking history, comorbidities, and symptoms for each of these tests.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>COVID-19 Infection</condition>
  <arm_group>
    <arm_group_label>Diagnostic (biospecimen collection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo collection of nasopharyngeal (back of the nose) samples by a medical provider and self-collection of oral, saliva, and nasal samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of nasopharyngeal, oral, saliva, and nasal samples</description>
    <arm_group_label>Diagnostic (biospecimen collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Demographic information, sample collection type preferences; clinical outcome information</description>
    <arm_group_label>Diagnostic (biospecimen collection)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Qualifies for SARS-CoV-2 testing at MD Anderson, Lyndon B. Johnson (LBJ) hospital, or
             affiliated sites (may include MD Anderson and LBJ patients and employees) according to
             institutional criteria at time of enrollment

          -  Willing and able to provide informed consent

          -  Ability to perform protocol-required activities

          -  Able to speak and read English or Spanish

        Exclusion Criteria:

          -  Patient or provider decision not to perform SARS-CoV-2 testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Schmeler</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen M Schmeler</last_name>
    <phone>73-745-3518</phone>
    <email>kschmele@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lyndon Baines Johnson General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026-1967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen M. Schmeler</last_name>
      <phone>713-745-3518</phone>
    </contact>
    <investigator>
      <last_name>Kathleen M. Schmeler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen M. Schmeler</last_name>
      <phone>713-745-3518</phone>
      <email>KSchmele@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen M. Schmeler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

